Dose finding study of Campath-1H in haploidentical HLA-mismatched hematopoietic stem cell transplantation for hematological malignancies

Dose finding study of Campath-1H in haploidentical HLA-mismatched hematopoietic stem cell transplantation for hematological malignancies - Dose-reducing study of Campath-1H

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000354

Enrollment

Registered

2006-03-10

Start date

2005-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies

Interventions

To find minimum tolerated dose by reducing the dose of Campath-1H with evaluation of the incidence of grade III to IV acute GVHD.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with hematological malignancies which can not be cured without transplantation. 2. Patients who have a 2- or 3-loci-mismatched haploidentical related donor with good physical condition.

Exclusion criteria

Exclusion criteria: 1. Patients who have an available HLA-A/B/DR-matched or 1-locus-mismatched donor in family members. 2. Patients who have an HLA-matched unrelated donor and whose disease status can wait for time-consuming donor coordination.

Design outcomes

Primary

Measure	Time frame
Donor cell engraftment and the incidence of grade III to IV acute GVHD within 60 days after transplantation	—

Secondary

Measure	Time frame
Relapse rate and non-relapse mortality at 1 year Overall survival at 1 year Immune reconstitution	—

Countries

Japan

Contacts

Public ContactYoshinobu Kanda

University of Tokyo Hospital Department of Hematology & Oncology

ycanda-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026